NICE guidance requires only the presence of activating EGFR mutations [17,21] for NSCLC patients to be eligible for EGFR inhibitors, meaning four patients with unusual EGFR mutations (M600T, S720C, V742I, and L861Q) received erlotinib as a result of the panel. Here, EGFR is linked to non-small cell lung carcinoma.